Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00049062 · ClinicalTrials.gov registry record · Phase 2
Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by The University of Texas Health Science Center at San Antonio.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00049062 is a Phase 2 study that has completed, run by The University of Texas Health Science Center at San Antonio.
The verdict
NCT00049062, a Phase 2 study, has completed, sponsored by The University of Texas Health Science Center at San Antonio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Anastrozole may fight breast cancer by blocking the production of estrogen by the tumor cells. Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of advanced solid tumors. Combining anastrozole with ZD 1839 may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining anastrozole with ZD 1839 in treating postmenopausal women who have metastatic breast cancer that has not responded to hormone therapy.
Interventions
- DRUG anastrozole
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-09 |
| Est. Completion | 2007-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00049062
The ClinicalTrials.gov registry entry for NCT00049062 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is The University of Texas Health Science Center at San Antonio, which has 378 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which anastrozole is the first listed.
NCT00049062 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00049062 about?
NCT00049062 is a clinical study titled "Anastrozole and ZD 1839 in Treating Postmenopausal Women With Metastatic Breast Cancer". RATIONALE: Estrogen can stimulate the growth of breast cancer cells. Anastrozole may fight breast cancer by blocking the production of estrogen by the tumor cells. Biological therapies such as ZD 1839 may interfere with the growth of the tumor cells and slow the growth of advanced solid tumors. Comb...
What is the current status of trial NCT00049062?
This trial is currently completed. It is a Phase 2 study. The study started on 2002-09. Estimated completion is 2007-10.
What interventions are being tested in trial NCT00049062?
The interventions under investigation include: anastrozole (DRUG), gefitinib (DRUG).
Who is sponsoring clinical trial NCT00049062?
This trial is sponsored by The University of Texas Health Science Center at San Antonio, which has 378 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.